<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02323451</url>
  </required_header>
  <id_info>
    <org_study_id>QS20140506</org_study_id>
    <nct_id>NCT02323451</nct_id>
  </id_info>
  <brief_title>Medical Chitosan or Sodium Hyaluronate for Knee Osteoarthritis (CHOOSE)</brief_title>
  <official_title>A Multicentre, Randomized, Double-blinded, Parallel-controlled, Non-inferiority Clinical Study Of Safety and Efficacy Of Medical Chitosan for Knee Osteoarthritis Compared With Sodium Hyaluronate Injection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Qisheng Biological Preparation Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Qisheng Biological Preparation Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the safety and efficacy of investigational products in the treatment of&#xD;
      knee Osteoarthritis. Half of participants will receive medical chitosan, while the other half&#xD;
      will receive sodium hyaluronate.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Medical chitosan and sodium hyaluronate each form the reticular layer to cover the joint&#xD;
      surface, alleviate the joint friction and pain. For medical chitosan, its half-life is longer&#xD;
      than sodium hyaluronate, so the interval time of intra-articular injection is longer.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2014</start_date>
  <completion_date type="Anticipated">April 2017</completion_date>
  <primary_completion_date type="Anticipated">August 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual Analogue Scale for knee pain</measure>
    <time_frame>six weeks of the initial injection</time_frame>
    <description>The investigator and the subject both evaluate the pain intensity per VAS before injection. VAS ranges from o to 10, 0=no pain, 10=pain as bad as can be.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>WOMAC for knee pain</measure>
    <time_frame>six weeks of the initial injection</time_frame>
    <description>WOMAC includes 3 items: pain, stiff and physiological function. 0=no, 4=as bad as can be.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">270</enrollment>
  <condition>Osteoarthritis, Knee</condition>
  <arm_group>
    <arm_group_label>Medical Chitosan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Medical Chitosan, 2ml/vial (12mg/ml), intra-articular injection with a volume less than 2ml every two weeks, a total of 3 times</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sodium Hyaluronate Injection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sodium Hyaluronate Injection, 2ml/vial (10mg/ml), intra-articular injection with a volume less than 2ml every one weeks, a total of 5 times.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Medical Chitosan</intervention_name>
    <description>intra-articular injection</description>
    <arm_group_label>Medical Chitosan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium Hyaluronate Injection</intervention_name>
    <description>intra-articular injection</description>
    <arm_group_label>Sodium Hyaluronate Injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males or females at the age of 40-75 years old&#xD;
&#xD;
          2. Conforming to the diagnosis standard of the American College of Rheumatology in 2009：&#xD;
             knee pain and osteophyte determined with X-ray, and at least one of the following&#xD;
             items：&#xD;
&#xD;
               -  above 50 years old&#xD;
&#xD;
               -  morning stiffness less than 30 minutes&#xD;
&#xD;
               -  knee joint with fricative when moving&#xD;
&#xD;
          3. The studying knee has score of 40-90 mm on a 100 mm measured VAS and the other side&#xD;
             was less than 40mm when walking on flat ground.&#xD;
&#xD;
          4. The studying knee has score of 1, 2 or 3 determined by radiological Kellgren-Lawrence&#xD;
             grading scale.&#xD;
&#xD;
          5. Patients who have treatment requirements and can obey the therapeutic schedule&#xD;
&#xD;
          6. Body mass index(BMI) ≤35kg/m2。&#xD;
&#xD;
          7. Able to follow the clinical observation and follow up.&#xD;
&#xD;
          8. The subjects are able to understand and sign the informed consent after fully&#xD;
             understand this study, the disease, investigational drugs, the therapeutic schedule&#xD;
             and the potential risks.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Positive signs of swelling or floating patella test，and there are obvious effusion of&#xD;
             knee joint in clinical.&#xD;
&#xD;
          2. Other inflammatory pain diseases of knee joint, such as rheumatism/ rheumatoid&#xD;
             arthritis, psoriatic arthritis, gout, hemophilic arthritis, etc.&#xD;
&#xD;
          3. Pain diseases of knee joint, except for osteoarthritis, such as intra-articular tumor,&#xD;
             villonodular synovitis, joint trauma, etc.&#xD;
&#xD;
          4. Pregnant or lactating females.&#xD;
&#xD;
          5. Participants who suffer from serious cardiovascular disease (Sudden cerebral&#xD;
             infarction with sequela or myocardial infarction within recent 6 months), hepatic&#xD;
             disease, kidney disease；Participants whose ALT and AST are twice or more than twice&#xD;
             than that of the upper limit of normal value；Participants whose serum creatinine&#xD;
             exceed the upper limit of normal value；Participants who suffer from dysfunction of&#xD;
             blood coagulation (thrombocytopenia, bleeder disease, etc.)&#xD;
&#xD;
          6. Participants who have systemic infection or infectious disease.&#xD;
&#xD;
          7. Participants who suffer from serious skin defect or ulcer around the studying knee&#xD;
             joint.&#xD;
&#xD;
          8. Participants who suffer from typical varus or valgus deformities or lack of articular&#xD;
             cavity.&#xD;
&#xD;
          9. Participants with diabetes and have to inject insulin or who are not good enough to&#xD;
             control the blood glucose (FBG ( fasting blood-glucose) ≥10mmol/L.)&#xD;
&#xD;
         10. Participants who suffer from cancer (within 5 years) or Alzheimer's disease.&#xD;
&#xD;
         11. Participants with score 0 or 4 of the studying knee joint evaluated by radiological&#xD;
             Kellgren-Lawrence grading scale.&#xD;
&#xD;
         12. Participants who have hormone drugs within 2 weeks or analgesic drugs within 1 week&#xD;
             before this trial or take part in other clinical trials.&#xD;
&#xD;
         13. Participants whose studying knee receives articular cavity therapy within 3 months,&#xD;
             containing intra articular administration, articular irrigation and arthroscopic&#xD;
             surgery&#xD;
&#xD;
         14. Participants with an allergy to the experimental drugs.&#xD;
&#xD;
         15. Participants who are not suitable for this trial judged by the researchers.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Changqing Zhang, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai,China.Shanghai Sixth People's Hospital. Orthopedics. Recruiting. No. 600. Yishan Rd. Shanghai. Post Code:200233.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shigui Yan, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hangzhou,Chian. The Second Affiliated Hospital of Zhejiang University School of Medicine. Orthopedics. Not yet recruiting. No.88 Jiefang Road Hangzhou.China Post Code：310009</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Changqing Zhang, PhD</last_name>
    <phone>+86-13003104089</phone>
    <email>zhangcq@sjtu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shengbao Chen, MD</last_name>
    <phone>+86-18930172088</phone>
    <email>shengbaocheng@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shanghai Sixth People's Hospital. Orthopedics.</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200233</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Changqing Zhang, PhD</last_name>
      <phone>+86-13003104089</phone>
      <email>zhangcq@sjtu.edu.cn</email>
    </contact>
    <contact_backup>
      <last_name>Shengbao Chen, MD</last_name>
      <phone>+86-18930172088</phone>
      <email>shengbaocheng@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <study_first_submitted>December 18, 2014</study_first_submitted>
  <study_first_submitted_qc>December 22, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2014</study_first_posted>
  <last_update_submitted>December 23, 2014</last_update_submitted>
  <last_update_submitted_qc>December 23, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 24, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chitosan</mesh_term>
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

